Inventor · disambiguated record
Torsten Hechler
Also filed as: HECHLER TORSTEN
12 granted patents·11 pending applications·13 citations·filing 2014–2024
85Inventor score
Top patents by PatentIndex Score
23 records- 0186US10842882B2Amatoxin-antibody conjugatesHEIDELBERG PHARMA GMBH·Filed 2016·Granted Nov 24, 2020·5 cites·9 claims
- 0280US11583569B2PSMA-targeting amanitin conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Feb 21, 2023·2 cites·18 claims
- 0375US11420971B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Aug 23, 2022·1 cites·8 claims
- 0475US10961277B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Mar 30, 2021·1 cites·9 claims
- 0575US2025064960A1B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 0674US12201693B2Amanitin conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2023·Granted Jan 21, 2025·0 cites·5 claims
- 0773US11590238B2Amanitin conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2017·Granted Feb 28, 2023·1 cites·6 claims
- 0872US2025009901A1Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapyHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 0971US12403201B2B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2022·Granted Sep 2, 2025·0 cites·8 claims
- 1070US11926631B2Method of treating cancer using amanitin derivativesHEIDELBERG PHARMA RES GMBH·Filed 2022·Granted Mar 12, 2024·0 cites·4 claims
- 1170US9982018B2Amatoxin derivativesHEIDELBERG PHARMA GMBH·Filed 2014·Granted May 29, 2018·2 cites·24 claims
- 1268US11446388B2Amanitin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2017·Granted Sep 20, 2022·1 cites·3 claims
- 1367US2025186606A1Modular linker compound for target-binding drug conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 1464US11702451B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Jul 18, 2023·0 cites·20 claims
- 1563US2025195675A1New antibody-drug conjugate as well as methods of production and uses thereofHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 1663US2024307549A1Subcutaneously administered antibody-drug conjugates for use in cancer treatmentHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 1762US2024165257A1Anti-gucy2c antibody and uses thereofHEIDELBERG PHARMA RES GMBH·Filed 2023·Application pending·0 cites
- 1861US2022133902A1Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer TherapyHEIDELBERG PHARMA RES GMBH·Filed 2021·Application pending·0 cites
- 1960US2023355792A1Methods of improving the therapeutic indexHEIDELBERG PHARMA RES GMBH·Filed 2023·Application pending·0 cites
- 2058US2025171419A1Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereofHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 2152US2024082416A1Amatoxin analogs and uses thereofUNIV BRITISH COLUMBIA·Filed 2021·Application pending·0 cites
- 2251US11976131B2Humanized antibodies against PSMAHEIDELBERG PHARMA RES GMBH·Filed 2019·Granted May 7, 2024·0 cites·20 claims
- 2348US2025195678A1B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Torsten Hechler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →